Solventum Corporation
SOLVHealthcareNASDAQMedical Instruments & Supplies · Last scanned Jul 17, 2026
Scan Results
Daily timeframeSolventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. With a market capitalization of $14.15B, it sits in large-cap territory. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems.
Market Cap
$14.15B
Beta
0.72
P/E (TTM)
9.60
P/E (Fwd)
11.53
EPS (TTM)
$8.51
EPS (Fwd)
$7.09
ROE
34.8%
ROA
2.8%
Cash
$561.0M
Total Debt
$5.29B
Free CF
$377.5M
52W Change
10.6%
Annual Financials
Cash vs Debt
Solventum Corporation carries $5.29B in total debt against $561.0M in cash reserves — debt is roughly 9.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $377.5M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 34.8% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.8% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $8.13B (2022) to $8.32B (2025).
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Solventum Corporation and its sector.